High-Sensitivity Troponin as a Biomarker in Heart Rhythm Disease

• Published in: The American journal of cardiology Vol. 119; no. 9; pp. 1407 - 1413
• Main Authors: McCarthy, Cian P., MB BCh, BAO, Yousuf, Omair, MD, Alonso, Alvaro, MD, PhD, Selvin, Elizabeth, MPH, PhD, Calkins, Hugh, MD, McEvoy, John W., MB BCh, BAO, MHS
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2017; Elsevier Limited
• Subjects: Acute coronary syndromes; Arrhythmia; Arrhythmias, Cardiac - blood; Arrhythmias, Cardiac - complications; Arrhythmias, Cardiac - epidemiology; Biomarkers; Biomarkers - blood; Calcium-binding protein; Cardiac arrhythmia; Cardiomyopathy; Cardiovascular; Cardiovascular disease; Complications; Coronary artery; Coronary artery disease; Damage detection; Death, Sudden, Cardiac - epidemiology; Death, Sudden, Cardiac - etiology; Electrophysiology; Fibrillation; Health risk assessment; Health risks; Heart; Heart attacks; Heart diseases; Heart failure; Humans; Literature reviews; Mortality; Patients; Pharmacology; Population; Prognosis; Rhythm; Risk Assessment; Sensitivity; Stroke; Troponin; Troponin - blood
• ISSN: 0002-9149; 1879-1913
• DOI: 10.1016/j.amjcard.2017.01.032

Biomarkers are important prognostic tools in various cardiovascular conditions, including coronary artery disease and heart failure. Although their utility in cardiac electrophysiology (EP) is less established, biomarkers may guide EP clinical practice by identifying patients at risk for developing arrhythmias and their complications, in addition to augmenting therapeutic decisions by targeting appropriate pharmacologic and interventional therapies to patients who may benefit most. In this review, we focus on the prognostic role of high-sensitivity cardiac troponin (hs-cTn) assays—which detect subclinical cardiac myocyte damage—in cardiac arrhythmias and their sequelae. We review the current literature on hs-cTn and its impact on various arrhythmia disease states and also provide suggestions for future research in this field. In conclusion, although the utility of hs-cTn assays remains at an investigational stage in cardiac EP, studies to date have suggested value as a prognostic biomarker in atrial fibrillation and as a screening marker for patients at high risk of sudden cardiac death (both in the general population and among those with hypertrophic cardiomyopathy).